Showing 1841-1850 of 3223 results for "".
- Allotex Secures Funding for Allogeneic Presbyopia Inlayshttps://modernod.com/news/allotex-secures-funding-for-allogeneic-presbyopia-inlays/2481717/Allotex and SpA announced the first close of its $30 million Series B financing to support the further development of its technology for the treatment of refractive errors. The investment was driven by 4-year data on presbyopia and hyperopia treatments, confirming significant impro
- Elios Vision Announces Collaboration with the International Glaucoma Surgical Registryhttps://modernod.com/news/elios-vision-announces-collaboration-with-the-international-glaucoma-surgical-registry/2481708/Elios Vision has announced its collaboration and support for the International Glaucoma Surgical Registry (IGSR), an open access tool which enables surgeons to upload and analyze their data and compare outcomes with other centers. The IGSR was established more than 5 years ago and currently
- Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Trial of ADX‑2191 in Patients with RPhttps://modernod.com/news/aldeyra-therapeutics-announces-improvement-from-baseline-in-retinal-function-in-phase-2-clinical-trial-of-adx2191-in-patients-with-rp/2481703/Aldeyra Therapeutics announced positive topline results from the phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa (RP). Relative to baseline, the clinical trial demonstrated statistically s
- Elios Vision Completes Enrollment in US Pivotal Trial; Expands US Pre-Launch Teamhttps://modernod.com/news/elios-vision-completes-enrollment-in-us-pivotal-trial-expands-us-pre-launch-team-and-continues-to-generate-commercial-uptake-in-europe/2481701/Elios Vision announced it has completed enrollment for its pivotal trial of more than 300 patients with mild to moderate glaucoma treated with the Elios procedure in combination with cataract surgery. Elios is an implant-free procedure that uses excimer laser technology for the treatmen
- SriniVas R. Sadda, MD, Named 2023-2024 ARVO President Electhttps://modernod.com/news/srinivas-r-sadda-md-named-2023-2024-arvo-president-elect/2481697/Doheny Eye Institute announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 annual meeting in New Orleans. Dr. Sadda has been a member of ARVO for a number of years, and s
- Bruder Healthcare Expands Dry Eye Portfolio with Eye Care Distribution of AllerFocus Percutaneous Allergy Testhttps://modernod.com/news/bruder-healthcare-expands-dry-eye-portfolio-with-eye-care-distribution-of-allerfocus-percutaneous-allergy-test/2481689/Bruder Healthcare announced an eye care industry distribution agreement with Tallahassee, Florida-based AllerFocus for its Percutaneous Allergy Test, a needle-free allergy screening for 78 of the most common airborne and environmental allergens. Financial terms of the deal w
- FDA Rejects Aldeyra's NDA for Rare Eye Cancer Drug ADX-2191https://modernod.com/news/fda-rejects-aldeyras-nda-for-rare-eye-cancer-drug-adx-2191/2481684/The FDA issued a Complete Response Letter to Aldeyra Therapeutics for the NDA of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate for the treatment of primary vitreoretinal lymphoma (PVRL). Although no safety or manufacturing issues with ADX-2191 w
- Alcon to Showcase Innovations for Eye Care Practice Success at 2023 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-innovations-for-eye-care-practice-success-at-2023-optometrys-meeting/2481682/Alcon will showcase innovations from advances in the reusable lens space to digital offerings at Optometry’s Meeting, the American Optometric Association (AOA) annual conference taking place June 21-24 in Washington, D.C. Through interactive events, Q&A’s, live demonstrations, and
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis-1/2481676/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE-2 clinical trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational new drug, in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for t
- Alcon Announces Results of the Alcon Eye On Cataract Surveyhttps://modernod.com/news/alcon-announces-results-of-the-alcon-eye-on-cataract-survey/2481672/Alcon announced the results of the Alcon Eye On Cataract Survey, which was conducted between March and April 2023 in Australia, Brazil, China, Germany, India, Italy, Japan, Spain, South Korea and the United States. The survey set out to evaluate vision and cataract insights among the wo